{"id":"W4318754961","doi":"10.1016/j.euo.2023.01.010","title":"Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study","year":2023,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"ca_institutions":"Western University","funders":"National Cancer Institute; Eisai Incorporated; Genentech; Ipsen; Astellas Pharma; EUSA Pharma; Seagen; Sanofi; Exelixis; Memorial Sloan-Kettering Cancer Center; Merck Sharp and Dohme; Ono Pharmaceutical; Eisai; Merck KGaA; Handok; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer","keywords":"Medicine; Lenvatinib; Sunitinib; Pembrolizumab; Renal cell carcinoma; Internal medicine; Oncology; Everolimus; Subgroup analysis; Kidney cancer; Response Evaluation Criteria in Solid Tumors; Clinical trial; Cancer; Phases of clinical research; Meta-analysis; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003144286,0.0004299113,0.001909291,0.0008441316,0.00008818533,0.000009467412,0.0004314587,0.00008742572,0.0001051775],"category_scores_gemma":[0.000775705,0.0003090879,0.000274668,0.001236386,0.001022954,0.00007267524,0.0003514107,0.0005498801,0.00001060948],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002059795,"about_ca_system_score_gemma":0.0004295357,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003179611,"about_ca_topic_score_gemma":0.0003542022,"domain_scores_codex":[0.9892439,0.007626866,0.001263325,0.0008183619,0.0005333136,0.0005142906],"domain_scores_gemma":[0.9931972,0.004711346,0.0008792083,0.0007942985,0.0002176351,0.0002003378],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8808658,0.004104487,0.04602438,0.0000529484,0.001789707,0.002898904,0.002773534,0.0006412493,0.05985764,0.00001207127,0.0005963048,0.0003829979],"study_design_scores_gemma":[0.6517559,0.02001391,0.3069261,0.00001182794,0.007257105,0.00007859543,0.002059544,0.001621253,0.009411206,9.911256e-7,0.0005664837,0.0002971342],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9940331,0.0003973542,0.00005021282,0.0003848234,0.0002151754,0.001725693,0.0004216084,0.00003590065,0.002736149],"genre_scores_gemma":[0.9982636,0.0000367103,0.000175799,0.0001009096,0.0000269314,0.00006426022,0.0008465266,0.00006951039,0.0004157557],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2609017,"threshold_uncertainty_score":0.9999361,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03463152331413209,"score_gpt":0.3178959216777795,"score_spread":0.2832643983636474,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}